Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03516279 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
A Phase 2 study of Minimal Residual Disease and Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, sponsored by ECOG-ACRIN Cancer Research Group.
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 20
- Study locations
NCT03516279 is a Phase 2 study of Minimal Residual Disease and Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive that is active but no longer recruiting, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 40 participants, below the 12,577-participant average among 8 other Minimal Residual Disease trials with a reported enrollment target (100% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT03516279, a Phase 2 study of Minimal Residual Disease and Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, is active but no longer recruiting, sponsored by ECOG-ACRIN Cancer Research Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product called bcr-abl in the blood. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Dasatinib, imatinib mesylate, and nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and dasatinib, imatinib mesylate, or nilotinib may work better in treating patients with chronic myeloid leukemia.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- OTHER Laboratory Biomarker Analysis
- DRUG Dasatinib
- DRUG Nilotinib
- DRUG Imatinib Mesylate
Study Locations (20)
California
- Mission Hope Medical Oncology - Arroyo Grande - Arroyo Grande
- Mercy Cancer Center - Carmichael - Carmichael
- Mercy San Juan Medical Center - Carmichael
- Mercy Cancer Center - Elk Grove - Elk Grove
- Contra Costa Regional Medical Center - Martinez
- Mercy Cancer Center - Merced
- Mercy Cancer Center - Rocklin - Rocklin
- Mercy Cancer Center - Sacramento - Sacramento
- Pacific Central Coast Health Center-San Luis Obispo - San Luis Obispo
- Mission Hope Medical Oncology - Santa Maria - Santa Maria
- BASS Medical Group - Lennon - Walnut Creek
- Woodland Memorial Hospital - Woodland
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
- CHI Saint Vincent Cancer Center Hot Springs - Hot Springs
- CARTI Cancer Center - Little Rock
Arizona
- CTCA at Western Regional Medical Center - Goodyear
- Cancer Center at Saint Joseph's - Phoenix
Colorado
- Rocky Mountain Cancer Centers-Aurora - Aurora
- Boulder Community Foothills Hospital - Boulder
Alaska
- Fairbanks Memorial Hospital - Fairbanks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-06-26 |
| Est. Completion | 2031-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03516279
The ClinicalTrials.gov registry entry for NCT03516279 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,577-participant average among 8 other Minimal Residual Disease trials with a reported enrollment target (100% lower). The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Minimal Residual Disease appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT03516279 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arkansas, Arizona.
Frequently Asked Questions
What is clinical trial NCT03516279 about?
NCT03516279 is a clinical study titled "Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease". This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product called bcr-abl in the blood. Monoclonal antibodies, ...
What is the current status of trial NCT03516279?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2019-06-26. Estimated completion is 2031-08-31.
What conditions does trial NCT03516279 study?
This clinical trial studies the following conditions: Minimal Residual Disease, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive.
What interventions are being tested in trial NCT03516279?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER), Dasatinib (DRUG), Nilotinib (DRUG), Imatinib Mesylate (DRUG).
Who is sponsoring clinical trial NCT03516279?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03516279 being conducted?
This trial has 20 study locations across Alaska, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Minimal Residual Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease
COMPLETED · Phase 2
-
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
RECRUITING · Phase 1
-
Caris Biorepository Research Protocol
RECRUITING
-
CtDNA Based MRD Testing for NAC Monitoring in TNBC
RECRUITING
-
Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Minimal Residual Disease
All registered trials for this condition
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
All registered trials for this condition
Alaska
All trials with a study site in Alaska
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.